|
KMID : 0378019870300040104
|
|
New Medical Journal
1987 Volume.30 No. 4 p.104 ~ p.110
|
|
|
Clinical Trial of Tenoxicam (Ro 12-0068) in Patients with Extra-articular Musculoskeletal Inflammatory Conditions
|
|
|
|
|
Abstract
|
|
|
Anti-inflammatory effect and tolerability of Tenoxicam for the patients with extra-articular musculoskeletal inflammatory conditions were determined by way of the double blind parallel group trial with Viroxicam. 20mg of Tenoxicam and the same amount of Piroxicam were given to each group of 30 patients 1 time per a day before breakfast for 14 days.
The results were as follows:
1. Clinical efficacy of Tenoxicam was shown as excellent and good 70%, moderate 16.6% and bad 13.3%, whereas that of Prioxicam was excellent and good 73.4%, moderate 20% and bad 6.7%.
2. Tolerability of tenoxicam was shown as excellent 70%, good 20%, moderate 6.7% and bad 3.2%, and that of Piroxicam was excellent 56.7%, good 33.3%, moderate 3.3% and bad 6.7%.
3. Overall judgement based on efficacy and tolerability of Tenoxicam was shown as excellent and good 63.4%, moderate 23.3% and bad 13.3%, and the result of Piroxciam was excellent and good 4.3%, moderate 13.3% and bad 13.3%.
4. Noted adverse reactions in Tenoxicam group were facial edema, dizziness and gastric discomfort in one patient respectively and those of Prioxicam group were 3 patients of gastrointestinal troub e and one case of skin rash.
5. Although there were some difference between the results of 2 groups, there was no statistical difference.
From the above results, we could conlclude that Tenoxicam is an effective and safe agent for the extraarticular musculoskeletal inflammatory conditions.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|